Christian Husegaard at Bang & Olufsen Medicom discusses how the market is now evolving towards more user-friendly injection systems, as evidenced by the emergence of next-generation, disposable auto injectors for various treatments
An increasing proportion of pipeline drugs and drug introductions are administered by injection. However, the development of corresponding injection devices has not been able to keep up with the development of these large molecule drug formulations, leaving an increasing number of patients to administer their own treatment by use of unwieldy and complicated devices.
THE GAP
The pharmaceutical biotechnology industry has contributed to the growth in injectable drugs, and is now a major driver in new drugs coming to the market. Despite the progress made in developing new and innovative treatments for a wide range of therapeutic areas, this does not appear to have been matched by the development in drug delivery solutions, creating a ‘quality gap’ between the two elements that should in practice be working together – the drug and the device. |